A supplemental New Drug Application (sNDA) for Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) has been accepted for Priority Review by the US FDA. The application is to ...
Takeda has announced new data from the two pivotal phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results